Compare Build A Bear Workshop Inc (BBW) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Build A Bear Workshop Inc vs Recursion Pharmaceuticals Inc — how do they compare? Build A Bear Workshop Inc trades at $32.95 (market cap $412.61M), while Recursion Pharmaceuticals Inc trades at $3.36 (market cap $1.78B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 4.3× Build A Bear Workshop Inc's market cap, and Build A Bear Workshop Inc pays a 2.8% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| BBW | RXRX | |
|---|---|---|
Market Cap | $412.61M | $1.78B |
Sector | Consumer Cyclical | Health |
52-Week High | $75.85 | $6.79 |
52-Week Low | $29.84 | $2.84 |
Enterprise Value | $512.05M | $1.19B |
Dividend Yield | 2.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Build-A-Bear Workshop (BBW) trades at $33.62, down 2.32% with a bullish technical signal and strong valuation metrics including a P/E of 7.71 and P/S of 0.81. The company maintains solid profitability with 10.48% net margins and 35.87% ROE, while recent earnings have consistently beaten expectations. CEO transition to Chris Hurt in June 2026 and new product launches support growth initiatives.
BBW presents compelling value with analyst consensus target of $62.50 (86% upside) and 73% buy ratings. Strong fundamentals and debt-free balance sheet support long-term growth, though near-term headwinds include consumer spending pressure and international expansion execution risks.
RXRX trades at $3.30, down 7.3% today, with bearish technical signals from moving averages and oscillators. The clinical-stage biotech shows severe financial strain with a -851.51% net income margin and negative cash flow from operations of -$372M in 2025, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights AI-driven drug discovery potential but questions commercial viability.
Despite analyst consensus price target of $7.83 suggesting 137% upside, high cash burn and unproven business model pose substantial risk. Investment appeal hinges on successful drug development milestones, but current fundamentals indicate speculative positioning suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Build A Bear Workshop Inc
Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.
Read more on BBW →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
